| http://www.w3.org/ns/prov#value | - Three acetylcholinesterase inhibitors are currently approved for the treatment of mild to moderate Alzheimer disease (AD) in the U.S. While they extend the half-life of acetylcholine in the central nervous system, they also heighten acetylcholinergic transmission in peripheral tissues, which leads to side effects including a slow heart rate, gastrointestinal irritation, and sweating.
|
